New obesity drug formulation put to the test
NCT ID NCT07407348
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study is testing whether two different versions of the drug survodutide are equally effective in the body. It involves 80 healthy overweight or obese adults who will receive both formulations in a crossover design. The goal is to see if the new formulation matches the original in terms of drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- survodutide
- What this could lead to
- If successful, this could confirm that a new formulation of survodutide works as well as the original, potentially leading to a more convenient or cheaper treatment for obesity.
- What could go wrong
- This is an early phase 1 trial focused on drug levels in the body, not on weight loss or health outcomes. It may not lead to a better treatment, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Quotient Sciences
RECRUITINGNottingham, NG11 6JS, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Can a Two-Drug combo tip the scales against obesity?